Payment overview · 2025
General Payments
$311.31
17 reported records · 7 companies
Healthcare provider profile · identity verified
Philip Gibbs, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ABERDEEN, WA · NPI 1548283617
Verified facts
What the public records show
CMS Open Payments records show Philip Gibbs, MD received $311.31 in general payments during 2025 across 17 reported records.
Novartis Pharmaceuticals Corporation accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 471 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $104.97 | 33.7% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.57 | 15.3% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.62 | 11.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.39 | 10.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.70 | 10.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.91 | 9.6% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.15 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.31 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $104.97 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.57 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.62 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.39 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
471 | 78 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 874 | 196 |
| Lisinopril | Lisinopril | 651 | 142 |
| Eliquis | Apixaban | 471 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 61 |
| Furosemide | Furosemide | 312 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 65 |
| Losartan Potassium | Losartan Potassium | 279 | 57 |
| Carvedilol | Carvedilol | 268 | 58 |
| Omeprazole | Omeprazole | 268 | 53 |
| Metformin Hcl | Metformin Hcl | 240 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 42 |
| Atenolol | Atenolol | 213 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 41 |
| Sotalol | Sotalol Hcl | 189 | 38 |
| Potassium Chloride | Potassium Chloride | 173 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 36 |
| Gabapentin | Gabapentin | 163 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 35 |
| Allopurinol | Allopurinol | 151 | 24 |
| Spironolactone | Spironolactone | 139 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 30 |
| Mirtazapine | Mirtazapine | 137 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 31 |
| Warfarin Sodium | Warfarin Sodium | 128 | 25 |
| Xarelto | Rivaroxaban | 118 | 18 |
| Lorazepam | Lorazepam | 115 | 24 |
| Ezetimibe | Ezetimibe | 113 | 26 |
| Methenamine Hippurate | Methenamine Hippurate | 107 | 21 |
| Trazodone Hcl | Trazodone Hcl | 106 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 99 | 23 |
| Azithromycin | Azithromycin | 97 | 76 |
| Digoxin | Digoxin | 95 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 26 |
| Januvia | Sitagliptin Phosphate | 76 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 14 |
| Methylprednisolone | Methylprednisolone | 72 | 48 |
| Farxiga | Dapagliflozin Propanediol | 67 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 16 |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 64 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 26 |
| Finasteride | Finasteride | 59 | 13 |
| Tramadol Hcl | Tramadol Hcl | 58 | 18 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 55 | 15 |
| Doxepin Hcl | Doxepin Hcl | 54 | 11 |
| Prednisone | Prednisone | 54 | 16 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Valsartan | Valsartan | 53 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Torsemide | Torsemide | 51 | 12 |
| Fluconazole | Fluconazole | 50 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 37 |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Risperidone | Risperidone | 48 | 11 |
| Nabumetone | Nabumetone | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 15 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 44 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Colchicine | Colchicine | 42 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 26 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Taltz Autoinjector | Ixekizumab | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.31 · 17 records | Novartis Pharmaceuticals Corporation | ENTRESTO, Kerendia, LEQVIO, NEXLETOL, REPATHA, VOQUEZNA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error